Risk factors for central nervous system metastasis in patients with metastatic breast cancer
- PMID: 17848738
- DOI: 10.1007/BF02698034
Risk factors for central nervous system metastasis in patients with metastatic breast cancer
Abstract
Aims: Patients with metastatic breast cancer (MBC) and central nervous system (CNS) involvement have an impaired survival and quality of life. In this study, we investigated the risk factors for CNS metastasis among patients with MBC.
Methods: The risk factors for development of CNS metastasis were analyzed in 154 patients with MBC. Expression of c-erbB-2, Ki-67, p53, and hormone receptors was examined by immunohistochemistry (IHC) in breast cancer tissue samples from the 154 patients. Kaplan-Meier and log-rank tests were used for the analysis of overall survival (OS). Chi-square test was used for univariate analysis.
Results: Median OS was significantly poorer for patients with CNS metastasis as compared with patients with no CNS metastasis (OS, 23 mo vs 30 mo, respectively;p = 0.03). Ki-67 and p53 overexpressions by IHC, and lung metastasis as the first site of relapse, were associated with a higher risk of developing CNS metastasis in the univariate analysis (p <or= 0.05). The presence of lung metastasis (odds ratio [OR]= 2.82, 95% confidence interval [CI]: 1.13-7.00,p = 0.02) and p53 overexpression (OR = 2.44, 95% CI: 0.99-6.00,p = 0.05) were the two predictive factors associated with occurrence of CNS metastasis in the multivariate analysis.
Conclusions: In this study, the presences of lung metastasis as the first site of relapse and p53 overexpression were predictive for the occurrence of CNS metastasis in patients with MBC. Life expectancy of patients with CNS metastasis is significantly shorter than those without CNS metastasis. These results may have clinical significance in counseling MBC patients with regard to their prognosis.
Similar articles
-
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.Clin Cancer Res. 2019 Apr 15;25(8):2433-2441. doi: 10.1158/1078-0432.CCR-18-2366. Epub 2018 Dec 28. Clin Cancer Res. 2019. PMID: 30593513
-
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.Ann Oncol. 2003 Jul;14(7):1072-7. doi: 10.1093/annonc/mdg300. Ann Oncol. 2003. PMID: 12853349
-
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.Oncologist. 2007 Jul;12(7):766-73. doi: 10.1634/theoncologist.12-7-766. Oncologist. 2007. PMID: 17673608
-
Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge.Oncologist. 2008 Jul;13(7):739-50. doi: 10.1634/theoncologist.2008-0052. Epub 2008 Jul 9. Oncologist. 2008. PMID: 18614587 Review.
-
Prognostic factors after extraneural metastasis of medulloblastoma.Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):72-8. doi: 10.1016/j.ijrobp.2009.07.1729. Epub 2010 Feb 3. Int J Radiat Oncol Biol Phys. 2010. PMID: 20133080 Review.
Cited by
-
Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network.Mol Neurobiol. 2016 Jan;53(1):446-454. doi: 10.1007/s12035-014-9023-z. Epub 2014 Dec 4. Mol Neurobiol. 2016. PMID: 25465242 Review.
-
Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era.Neurooncol Pract. 2018 Aug;5(3):161-169. doi: 10.1093/nop/npx033. Epub 2017 Dec 23. Neurooncol Pract. 2018. PMID: 31386016 Free PMC article.
-
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies.Eur J Cancer. 2010 May;46(7):1204-10. doi: 10.1016/j.ejca.2010.02.033. Epub 2010 Mar 19. Eur J Cancer. 2010. PMID: 20303257 Free PMC article. Review.
-
A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer.Cancer Med. 2020 Nov;9(22):8540-8551. doi: 10.1002/cam4.3449. Epub 2020 Sep 18. Cancer Med. 2020. PMID: 32945619 Free PMC article.
-
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Ann Oncol. 2017. PMID: 28177431 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous